PRESS RELEASE published on 02/10/2026 at 07:30, 8 months 7 days ago Informations privilégiées / Autres communiqués L'Hôpital national des 15-20 et GenSight Biologics traitent le premier patient dans l'étude REVISE de GS010/LUMEVOQ contre la neuropathie optique héréditaire de Leber en France GenSight Biologics Neuropathie Optique GS010/LUMEVOQ Hôpital Des 15-20 Étude REVISE
PRESS RELEASE published on 02/10/2026 at 07:30, 8 months 7 days ago Inside Information / Other news releases 15-20 National Hospital and GenSight Biologics treat first patient in GS010/LUMEVOQ® REVISE Study, for Leber Hereditary Optic Neuropathy. Clinical study supported by ANSM and aiming to enroll 14 patients in France GenSight Biologics LHON GS010/LUMEVOQ REVISE Study 15-20 National Hospital
BRIEF published on 01/29/2026 at 00:26, 8 months 19 days ago GenSight Biologics publie les résultats de l'EGM Assemblée Générale Extraordinaire Actionnaires Augmentation De Capital GenSight Biologics Autorisations Financières
BRIEF published on 01/29/2026 at 00:26, 8 months 19 days ago GenSight Biologics Reports EGM Results Shareholders Capital Increase Extraordinary General Meeting GenSight Biologics Financial Authorizations
PRESS RELEASE published on 01/29/2026 at 00:21, 8 months 19 days ago Inside Information / Other news releases GenSight Biologics announces successful Extraordinary General Meeting approving financial authorizations renewal and clarifying rejection of 8th resolution, enhancing company's strategic flexibility Strategy Extraordinary General Meeting GenSight Biologics Gene Therapies Financial Authorizations
BRIEF published on 12/29/2025 at 08:05, 9 months 19 days ago GenSight Biologics Completes €2.9 Million Fundraising Shareholders Fundraising Gene Therapy Retinal Diseases Compassionate Use
BRIEF published on 12/29/2025 at 08:05, 9 months 19 days ago GenSight Biologics finalise une levée de fonds de 2,9 millions d'euros. Actionnaires Thérapie Génique Collecte De Fonds Maladies De La Rétine Usage Compassionnel
PRESS RELEASE published on 12/29/2025 at 08:00, 9 months 19 days ago Informations privilégiées / Autres communiqués GenSight Biologics réalise une levée de fonds de près de €2,9 millions d’euros pour développer des thérapies géniques innovantes. La société vise le traitement des maladies neurodégénératives de la rétine Levée De Fonds GenSight Biologics Thérapies Géniques Maladies Neurodégénératives Rétine
PRESS RELEASE published on 12/29/2025 at 08:00, 9 months 19 days ago Inside Information / Other news releases GenSight Biologics successfully raises nearly €2.9 million to fund gene therapies for retinal neurodegenerative diseases, plans to use proceeds for development and operational needs through 2026 Fundraising Proceeds GenSight Biologics Gene Therapies Retinal Diseases
BRIEF published on 12/22/2025 at 07:05, 9 months 26 days ago GenSight Biologics obtient une autorisation d'usage compassionnel pour GS010/LUMEVOQ® en France Thérapie Génique Maladies Rares Usage Compassionnel Traitement De La LHON Approbation ANSM
Published on 10/17/2026 at 03:20, 17 hours 2 minutes ago Battery X Metals Highlights Participation at X Takeover 2026, an Electric Vehicle and Emerging Technology Event Held at Tesla's Gigafactory Texas, Providing Exposure to Industry Perspectives and Technology Developments
Published on 10/17/2026 at 03:15, 17 hours 7 minutes ago Vanta Closes Second Tranche of Private Placement Financing and Welcomes Launch of First U.S.-Listed Peptide ETF, Highlighting Growing Recognition of Peptide Industry
Published on 10/16/2026 at 23:35, 20 hours 47 minutes ago Initial Closing of US$3.4 Million Private Placement
Published on 10/16/2026 at 23:30, 20 hours 52 minutes ago NiobiumX Mining Inc. Announces Retraction of Recent Marketing Materials
Published on 10/16/2026 at 23:00, 21 hours 22 minutes ago Grid Announces Adoption of Advance Notice By-Law and Provides Shareholder Meeting Update
Published on 10/17/2026 at 18:00, 2 hours 22 minutes ago Baader Bank announces extended trading hours 23 hours a day starting Q1/2027
Published on 10/17/2026 at 13:05, 7 hours 17 minutes ago Luong Quoi Coconut Vietnam to Showcase Vietnamese Coconut Expertise at SIAL Paris 2026
Published on 10/17/2026 at 12:50, 7 hours 32 minutes ago AGFUND wins international award for excellence in inclusive banking and social impact
Published on 10/16/2026 at 20:08, 1 day ago EQS-Adhoc: Rath AG // Rath Group reaches agreement with its key financial creditors on the terms of a transformation agreement and launches a transformation programme
Published on 10/16/2026 at 19:20, 1 day 1 hour ago Arity to Acquire INRIX, Advancing a Connected Vision for the Future of Transportation
Published on 10/16/2026 at 19:54, 1 day ago ENGIE - Déclaration du nombre total d'actions et de droits de vote au 30 septembre 2026
Published on 10/16/2026 at 18:48, 1 day 1 hour ago Disclosure of transactions in own shares from October 12 to October 16, 2026
Published on 10/16/2026 at 18:48, 1 day 1 hour ago Déclaration hebdomadaire d'opérations effectuées du 12 au 16 octobre 2026
Published on 10/16/2026 at 18:00, 1 day 2 hours ago KLARSEN : Compte rendu AGO et AGE du 8 octobre 2026
